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Immunotherapy for cancer is based on the concept of
inducing the generation and expansion of immune cells
that can attack and eliminate cancer. Immunotherapy with
therapeutic cancer vaccines aims speciﬁcally at inducing
tumor antigen-speciﬁc T cells. The immune system is a
complex, multifaceted cellular network that is not fully
understood. Monitoring cellular immune responses is essen-
tial for rational cancer vaccine development. The primary
objectives of immune monitoring after vaccination are to
document the induction of vaccine-speciﬁc and tumor-
speciﬁc immune responses and to correlate the presence
and magnitude of vaccine-induced immune responses to
clinical outcomes. Immune monitoring could also be used
to (a) deﬁne the ability of a given vaccine to generate antigen
cascade responses (i.e., epitope spreading); (b) compare the
eﬀects of vaccines of diﬀerent potencies; (c) evaluate the
ability of a given cytokine, drug, adjuvant, and so forth.
to enhance or hinder vaccine-induced immune responses;
(d) deﬁne appropriate patient populations for vaccine
studies; (e) study the presence and activity of inhibitory/
suppressor cell populations.
Despite advances in the development of immune mon-
itoring assays during the past decade, it has been diﬃcult
to establish signiﬁcant correlations between vaccine-induced
immune responses and clinical outcomes. This lack of
correlation could reﬂect the methodological limitations
of immunologic assays or the postvaccination absence of
antitumor responses suﬃciently robust to induce disease-
free oroverallsurvival. Awide portfolioofmonitoring assays
is currently available. However, these assays fail to deﬁne
surrogate markers that could be used as predictors of clinical
response and thus serve to advance vaccine development.
The immune monitoring assays currently used in cancer
immunotherapy trials (such as enzyme-linked immunospot
assays, tetramer-based assays, intracellular cytokine ﬂow
cytometry, antibody tests, proliferation assays, reverse tran-
scription polymerase chain reaction, and serum cytokine
and chemokine proﬁles) have limited usefulness as surrogate
markers of clinical eﬃcacy. There is general consensus that
further studies are needed to account for the diﬃculties
in establishing the correlation between diﬀerent aspects of
T-cell function and clinical eﬃcacy.
Vaccine-induced immune responses against cancer
depend on a balance between immune responses of var-
ious subsets of eﬀector and suppressor T cells. Because
tumor antigens are mostly self-antigens, this balance is
shifted toward tolerance in cancer patients, so that gen-
erating eﬀective antitumor responses requires breaking of
tolerance. Although preclinical data have shown that it
is possible to break tolerance to tumor-associated self-
antigens, human clinical trials employing cancer vaccines
have mostly failed to do so. In an immunocompetent cancer
patient, the immune system suppresses attacks against self-
antigens, including tumor-associated antigens, particularly
inthetumormicroenvironment. Recentstudieshavefocused
on deﬁning the role of the suppressive component of the
antitumor immune response in breaking tolerance and
steering the immune system toward autoimmunity. In this2 Journal of Biomedicine and Biotechnology
respect, monitoring assays that measure the extent of cancer-
induced suppression may be especially important.
The suppressive compartment of the immune system
includes a group of heterogeneous immune cells, includ-
ing regulatory T cells (Tregs), myeloid-derived suppressor
cells (MDSCs), and tumor-associated macrophages (TAMs).
Increased numbers and/or enhanced functionality of these
cellshavebeendetectedintheperipheralbloodmononuclear
cells, tumor microenvironment, and tumor-draining lymph
nodesofpatientswithhematologicmalignanciesandvarious
types of solid tumors. One of the major problems in
characterizing these cells is their extreme plasticity. Cells
normally committed to activating an immune response
can transiently acquire suppressive characteristics, as often
happens in cancer. While suppressor cells represent an
important mechanism by which the immune system ﬁne-
tunes speciﬁc immune responses, expansion of these cells
in cancer patients interferes with antitumor immunity. In
humans,ithasbeendiﬃculttoestablishadeﬁnitephenotype
for these cells, and assessment of their functional status
has been a special challenge as they are minor lymphocyte
subsets lacking well-deﬁned surface markers. Greater under-
standing of the mechanisms that regulate the homeostasis
of these suppressive cells could lead to the development of
more eﬀective cancer immunotherapies and better immune
monitoring of patients receiving cancer vaccines.
Several studies have demonstrated that Treg depletion
can eﬃciently enhance vaccine-mediated antitumor immu-
nity in cancer patients. For example, in a randomized
placebo-controlled multicenter phase II trial, 125 patients
with metastatic castration-resistant prostate cancer were
treated with a poxviral-based vaccine containing the trans-
genes for prostate-speciﬁc antigen and 3 costimulatory
molecules (PSA-TRICOM). This trial demonstrated a direct
correlation between the post-vaccination frequency and
function of Tregs and overall survival. Treg function and/or
phenotype, as well as the ratio of eﬀector to CTLA-4+
Tregs,couldpotentiallybeusedtomonitorimmunefunction
(the balance between immunostimulatory and immunosup-
pressive factors) in patients enrolled in clinical trials of
therapeutic cancer vaccines [1, 2]. Analysis of Tregs in real
time as part of the immune monitoring of patients could
alsohelptoidentifythesubpopulationofpatientswhowould
most likely beneﬁt from vaccine therapy.
Similar to Tregs, MDSCs are a heterogeneous cell popu-
lation that has been diﬃcult to monitor in humans. MDSCs
are composed mainly of myeloid progenitor cells that
do not completely diﬀerentiate into mature macrophages,
dendritic cells, or granulocytes. A recent study demonstrated
that a subpopulation of monocytic MDSCs, phenotypically
deﬁned as CD14+HLA-DR−/lo, is signiﬁcantly expanded in
patients with metastatic melanoma, hepatocellular carci-
noma, glioblastoma, and prostate cancer. Increased circu-
lating MDSCs have also been correlated with tumor stage
and metastatic spread in diﬀerent types of tumors [3,
4]. Moreover, it has been demonstrated that MDSCs can
be diﬀerently aﬀected by standard-of-care therapies such
as sunitinib, doxorubicin-cyclophosphamide, and docetaxel,
as well as some immunotherapies. These ﬁndings suggest
a potential use for these cells in immune monitoring of
cancer patients receiving immunotherapies.
Recent clinical studies have demonstrated a correlation
between increased numbers of TAMs and poor prognosis for
esophageal, bladder, prostate, endometrial, breast, and lung
cancers [5–8]. These data suggest a possible use of TAMs
in the immune monitoring of cancer patients enrolled in
clinical trials employing therapeutic vaccines.
While the major focus of post-vaccination monitoring is
assessment of tumorantigen-speciﬁc immuneresponses, it is
important to note that innate immunity mediated by natural
killer cells, macrophages, dendritic cells, or granulocytes
could signiﬁcantly contribute to beneﬁcial clinical outcome.
Vaccines that engage and promote adaptive and innate
antitumor responses appear to be most eﬀective. Thus, at
least some aspects of innate immunity should be monitored
in clinical trials of antitumor vaccines.
The increasing number of immunotherapy clinical trials
that use immunologic parameters as primary or secondary
endpoints, as well as the availability of an increasing number
of monitoring assays, highlights two aspects of immune
monitoring. First, selection of assays that are most likely
to correlate with clinical outcomes is a critical factor.
This should be an informed and hypothesis-driven choice,
considering factors such as cost and the need for serial
monitoring with multiple assays. As understanding of the
mechanisms of immune regulation increases, additional
biomarkers will be identiﬁed that, hopefully, can be used as
surrogate markers for immune responses to cancer vaccines.
Second, quality control and assurance are essential for suc-
cessful immune monitoring of cancer vaccines. All immune
monitoring assays need to be standardized for reliability
and consistency in order to establish their limitations and
overall performance standards. Immune monitoring assays
should be performed according to Good Laboratory Practice
guidelines, such as those recently formulated based on
recommendations from the iSBTc-SITC/FDA/NCI Work-
shop on Immunotherapy Biomarkers [9]. Only standard-
ized monitoring assays are likely to be useful for deﬁn-
ing surrogate endpoints of clinical response to antitumor
vaccines.
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